Kresge Eye Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Detroit MI United States (1948)

Organization Overview

First Clinical Trial
2005
NCT00915837
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Kresege Eye Institute | Kresge Eye Institute

Active Ingredients

Drugs in Phase 4 Trials (1)

fluorescein (1 trial)

Drugs in Phase 2 Trials (1)

thymosin beta-4 (1 trial)

Drugs in Phase 1 Trials (1)

triamcinolone (kenalog) (1 trial)

Drugs in Other Trials (2)

bevacizumab (avastin) (1 trial)

ranibizumab (lucentis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Edema (Phase 1)

Graft vs Host Disease (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Macular Edema (Phase 1)

Sjogren's Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5